Contact UsTwo Pershing Square 2300 Main Street, Suite 170 Kansas City MO 64108
Two Pershing Square
2300 Main Street, Suite 170
Kansas City, MO 64108
Telephone: (816) 221-6600
Toll Free: (877) 284-6600
Fax: (816) 221-6612
In May 2017, the FDA issued a safety warning indicating that Invokana, used to treat diabetes, could increase the risk of leg and foot amputations. This means that the drug now carries a boxed warning about the amputation risks. This is the strongest label warning that the FDA can require.
The black box warning required by the FDA informs patients that they could face a higher risk of needing an amputation after taking canagliflozin.
According to the FDA Safety communications, “based on new data from two large clinical trials, the U.S. Food and Drug Administration has concluded that the type 2 diabetes medicine canagliflozin (Invokana, Invokamet, Invokamet XR) causes an increased risk of leg and foot amputations. We are requiring new warnings, including our most prominent Boxed Warning, to be added to the canagliflozin drug labels to describe this risk.”
Despite the added warnings, the FDA has not required a recall or pulled the drug from the market. Instead, the FDA has provided some guidelines for those taking the medicine.
For more information or to report a serious problem:
Call 855-543-DRUG (3784) and press 4
Complete and submit the report Online.
Download the form or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-F DA-0178.
May 2015: The FDA issued a drug safety communications warning about the risk that SGLT2 inhibitors, such as Invokana and other diabetes drugs in the same class, may lead to ketoacidosis.
September 2015: The FDA revised the labels of Invokana and Invokamet to include information about bone fracture risk and decreased bone mineral density.
December 2015: The FDA warned patients to seek medical attention and stop using the drug at the first signs of ketoacidosis and added warnings of urinary tract infections that could be signs of serious blood infections or kidney failure.
June 2016: The FDA added a warning about SGLT2 kidney side effects, which was based on more than 100 adverse event reports submitted to the FDA.
May 2017: The FDA ordered a black box warning for the risk of toe, foot and leg amputations, which was based on the results of two clinical trials showing that patients with type 2 diabetes were twice as likely to need an amputation if they took Invokana than if they took a placebo.
Invokana has been linked to hundreds of adverse event reports of kidney failure, kidney damage, amputations and diabetic ketoacidosis.
Invokana lawsuits allege that the makers of the drug failed to adequately warn patients and the medical community about the potential risks and side effects of taking the drug.
Questions? Our knowledgeable staff is available at (877) 284-6600.
If you would like to receive news and blog updates on a regular basis, sign up to receive our email newsletter. Your email address will only be used to send you our newsletter and respond to inquiries.
Past results afford no guarantee of future results and each case is different and is judged on its own merits.